 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...1516171819202122232425...235236» |
- Adverse events in real-world patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX (FFX) or gemcitabine with nab-paclitaxel (GnP) in the first line (1L). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6898;
The burden of AEs was higher among the RW GnP cohort than the RW FFX cohort. G-CSF was more prevalent and began earlier in the FFX cohort, indicating prophylactic use.
- Association between somatic mutation pathways and treatment response in patients with biliary tract cancers (BTCs). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6896;
TP53 mutation is associated with a worse response, whereas cell cycle pathway mutations are associated with an improved response to gemcitabine and cisplatin therapy in patients with BTCs. Further research is needed to understand the mechanisms contributing to these observed effects.
- 5-fluorouracil / Generic mfg.
Efficacy of platinum chemotherapy agents in adenosquamous carcinoma of the pancreas. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6892;
Given the rarity of ASC, optimal management remains poorly defined, particularly in the postoperative period. Therapies based on platinum chemotherapeutics may be preferable to all other chemotherapy regimens.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Meta-analysis comparing the incidence of serious adverse events, overall survival, and progression-free survival in patients with pancreatic adenocarcinoma harboring unresectable tumors treated with modified FOLFIRINOX or FOLFIRINOX regimen. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6889;
Background: The evolution of first-line treatment for advanced pancreatic adenocarcinoma (PDAC) from Gemcitabine-based therapies to FOLFIRINOX-based regimens (fluorouracil, leucovorin, irinotecan, oxaliplatin) have demonstrated significant improvements in survival outcomes, however, this was associated with increased side effects such as neuropathy, fatigue, and diarrhea due to its heightened potency. In conclusion, modified FOLFIRINOX has maintained similar efficacy while reducing severe adverse events, making it more tolerable for adjuvant treatment after surgery.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Efficacy and safety of arterial FOLFOX chemotherapy plus anti-PD-(L)1 immunotherapy as first-line treatment for unresectable intrahepatic cholangiocarcinoma: A propensity score matched analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6871;
In conclusion, modified FOLFIRINOX has maintained similar efficacy while reducing severe adverse events, making it more tolerable for adjuvant treatment after surgery. HAIC plus anti-PD-(L)1 immunotherapy had acceptable toxic effects and might improve outcomes compared to SCT plus anti-PD-(L)1 immunotherapy as first-line treatment for patients with uICC.
- 5-fluorouracil / Generic mfg.
Analysis of effectiveness of FLOT perioperative chemotherapy in resectable locally advanced gastric or esophago-gastric junction cancer in a Kazakhstani population. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6556;
Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) perioperative chemotherapy is widely accepted treatment strategy of locally advanced gastric adenocarcinoma in Western countries. The FLOT perioperative chemotherapy was effective and feasible to administer and might be a standard treatment option among patients with locally advanced gastric or esophago-gastric junction cancer.
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Updated results of perioperative PD-1 antibody toripalimab plus FLOT chemotherapy for locally advanced resectable gastric or gastro-esophageal junction adenocarcinoma: A one-arm open-table phase II trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6527;
P2
MPR rate and NK cells in tumor microenvironment have a predictive on therapeutic efficacy, with deserves further study. Clinical trial information: NCT04354662.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin as a first line treatment for the management of metastatic pancreatic adenocarcinoma: A budget impact analysis from a U.S. payer perspective. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6475;
The model results indicate that the budget impact of NALIRIFOX may be minimal from a US health plan perspective. Given the poor prognosis of mPDAC, NALIRIFOX presents itself as an important new first line treatment option for people living with an aggressive and hard to treat cancer.
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
The safety and efficacy of immune checkpoint inhibitor in combination with FOLFOX as neoadjuvant/adjuvant therapy in patients with locally advanced colon cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5817;
P1/2
Tolerable adverse reactions suggest that neoadjuvant chemoimmunotherapy could potentially serve as a novel therapeutic option. Clinical trial information: NCT03985891.
- Avastin (bevacizumab) / Roche
FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated (mut) metastatic colorectal cancer (mCRC): An individual patient data-based pooled analysis of randomized trials. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5813;
P2, P3
Clinical trial information: NCT03985891. As compared to doublets/bev, upfront FOLFOXIRI/bev provides a meaningful advantage to pts with initially unresectable, liver-only, right-sided and/or RAS or BRAF mut mCRC, in terms of activity and efficacy, thus corroborating the choice of this regimen as upfront treatment for these pts, regardless of the opportunity to achieve the R0 secondary resection of their liver metastatic lesions.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
The treatment outcomes of patients with BRAFV600E () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5810;
According to the international guidelines in BRAFV600E mutated mCRC, the triplet chemotherapy FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, irinotecan) with bevacizumab and encorafenib plus cetuximab should be considered in 1st and 2nd line treatment setting, respectively...The majority of patients received doublet chemotherapy: FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin), FOLFIRI (folinic acid, 5-fluorouracil, irinotecan), XELOX (capecitabine, oxaliplatin), FOLFIRI and bevacizumab: 30 (30%), 47 (47%), 5 (5%), 3 (3%), respectively... This study highlights the unmet need for effective treatment strategies for patients with BRAFV600E mutated mCRC in Poland.
- 5-fluorouracil / Generic mfg.
Patient factors related to the real-world adoption of 3 months of adjuvant chemotherapy (ACT) in patients with stage III colorectal cancer (CRC). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5796;
6 mos of oxaliplatin is still being offered to pts with low-risk disease, and is associated with more neuropathy warranting early oxaliplatin cessation. Exploration of patient preferences and resource costs may improve more widespread adoption of 3 mos of adjuvant CAPOX in stage III CRC.
- Vectibix (panitumumab) / Amgen
Dermatology-related quality of life outcomes in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: A prespecified secondary analysis of the phase 2 randomized PanaMa (AIO KRK 0212) trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5789;
P2
These results suggest that patient reported outcomes by FACT-EGFRI, DLQI, and Skindex-16 reflect toxicity as recorded by classic toxicity scores which are not covered by global HRQOL assessment. These data, together with HRQOL may support clinical decision-making of maintenance therapy.
- 5-fluorouracil / Generic mfg.
Prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5787;
The developed machine learning models demonstrate potential for guiding clinicians in selecting the most effective treatment options based on individual genetic profiles. With additional clinical validation, this approach could lead to improvements in treatment outcomes for patients with CRC and other cancers.
- Avastin (bevacizumab) / Roche
Modified FOLFOXIRI plus bevacizumab as a salvage regimen for patients with refractory metastatic colorectal cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5781;
Background: The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab showed improved outcomes for patients with metastatic colorectal cancer (mCRC) as first-line systemic treatment. Modified FOLFOXIRI plus bevacizumab is effective as a salvage regimen in patients with refractory mCRC and with an acceptable safety profile.
- Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis
Preliminary efficacy and safety of total neoadjuvant therapy combined with PD-L1 blockade in pMMR/MSS locally advanced rectal cancer (ESTIMATE): A prospective, single-arm, phase II trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5775;
Long-term benefits need validation through further follow-up. Clinical trial information: ChiCTR2400079718.
- Impact of DNA damage repair alterations on real-world response to therapy in metastatic colorectal cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5770;
In these patients, TTNTD was greater with irinotecan-containing first line therapies (doublet or triplet). However, OS was similar regardless of which first-line chemotherapy was used.
- Stivarga (regorafenib) / Bayer
FOLFOX-based hepatic arterial infusion chemotherapy combined with regorafenib for unresectable colorectal liver metastases. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5764;
The mFOLFOX6 regimen was employed for HAIC, comprising oxaliplatin (85 mg/m2 for 2 h on day 1), calcium folinate (200 mg/m2 for 2 h on day 1), and 5-fluorouracil (5-Fu) administered as a bolus of 400 mg/m2 on day 1, followed by 2400 mg/m2 over 46 h. Regorafenib was administered orally at a dose of 160 mg (four 40 mg tablets) once daily for the first 21 days of each 28-day cycle, with HAIC performed during the 7 days of discontinuation. The combination of regorafenib with FOLFOX-HAIC exhibits substantial promise in managing unresectable CRLM, providing meaningful effectiveness without exacerbating toxicity.
- Evaluating peripheral myeloid-derived suppressor cells as factor for the diagnosis and treatment efficiency of patients with colorectal cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5718;
Additionally, first-line chemotherapy FOLFOX and XELOX, or chemotherapy plus targeted therapy can effectively reduce total MDSCs (13... This study disclosed that peripheral MDSCs have important diagnostic value and clinical significance for CRC.
- Prediction models of locally advanced rectal cancer prognosis incorporating perioperative longitudinal clinical data: A retrospective longitudinal cohort study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5712;
This multicenter retrospective data-driven deep learning prediction model informed that SVC model yielded the best predictive results. Further prospective clinical trials and external validation of this prediction model are needed to further reinforce our findings.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
A real-world experience of hepatic arterial infusion chemotherapy combined with tislelizumab and lenvatinib for unresectable hepatocellular carcinoma with type IV portal vein tumor thrombus. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5468;
Pts received HAIC of modified FOLFOX (oxaliplatin, 85 mg/m2; leucovorin, 400 mg/m2; 5-fluorouracil bolus, 400 mg/m2 on day 1; 5-fluorouracil infusion, 2400 mg/m2 for 46 h), lenvatinib (8 or 12 mg once daily for body weight, 60 or ?60 kg), and tislelizumab (200 mg q3w)...4%), HAIC+Tisle+Regorafenib (5... The combination of HAIC with tislelizumab and lenvatinib represents a promising efficacy and manageable safety for uHCC pts with Vp4, which supplements the trial data for Vp4-HCC with real world outcomes.
- Molecular and clinical features of pancreatic acinar cell carcinoma: A single institutional experience. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5449;
Better treatment outcome of FOLFIRNIOX/ platinum-based regimens was suggested based on this limited patient dataset. Larger studies are needed to further understand the molecular features of ACC and guide the treatment of this rare entity of pancreatic cancer.
- Benlysta (belimumab) / GSK, AiTan (rivoceranib) / HLB Bio Group
The safety and efficacy of adebelimumab combined apatinib and hepatic artery infusion chemotherapy in the treatment of unresectable hepatocellular carcinoma: A retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5427;
Background: The combination of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) used for hepatic arterial infusion chemotherapy (HAIC) has shown promise for advanced hepatocellular carcinoma (HCC) patients. The combination of Adebelimumab, apatinib, and FOLFOX-HAIC demonstrated manageable safety and encouraging results for unresectable HCC.
- Imfinzi (durvalumab) / AstraZeneca, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5422;
Lenvatinib plus durvalumab combined with FOLFOX-HAIC showed promising antitumor activity and manageable AEs in patients with treatment-naive unresectable ICC. This regimen may be suitable as a novel first-line treatment option for this patient population.
- 5-fluorouracil / Generic mfg.
Hepatic artery infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced hepatocellular carcinoma with portal vein tumor thrombus: A single center retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5415;
This study further demonstrates the clinical benefit of HAIC plus ICIs and TKIs for HCC pts with PVTT. In the future, prospective studies are warranted.
- Oncorine (recombinant human adenovirus type 5) / Mergen Ltd.
Efficacy of oncolytic virus combined with HAIC of mFOLFOX for IMCC: A single-center, single-arm, prospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5410;
P4
Meanwhile, this strategy has an effect on relieving the pain and malnutrition of long-term biliary drainage and improving the quality of life of patients. Even more, the OVs plus HAIC regimen may be more effective, if combined with the immune checkpoint inhibitors in the future.
- tadalafil / Generic mfg.
Modifying the gastric tumor microenvironment with tadalafil: A transcriptomic analysis of immune signatures from underserved patients of southern Arizona. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5391;
P2
Preliminary data of this ongoing study show that tadalafil treatment combined with FLOT, has the potential to decrease SLFN12L+ MDSC, to attenuate their immunosuppression, and potentially inhibit tumor progression. The trial is active and further analysis will be presented in due course.
- Zepsun (donafenib) / Suzhou Zelgen
TACE-HAIC combined with donafenib and immunotherapy for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A retrospective analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5380;
Of 106 patients included in the analysis, all of them received first-line treatment of TACE (embolization of pirarubicin hydrochloride 40mg, iodized oil 10-20ml with or without gelatin sponge) plus HAIC (oxaliplatin 85 mg/m2 2h, leucovorin 400 mg/m2 1h, fluorouracil bolus 400 mg/m2 in the first 10 minutes, and fluorouracil infusion 2400 mg/m2 for 46h) combined with donafenib 200mg bid, anti-PD-1 antibody Q3W. TACE-HAIC combined with Donafenib and immunotherapy are effective and tolerable for uHCC patients with PVTT.
- albumin-bound paclitaxel / Generic mfg.
Effectiveness and safety of irreversible electroporation when used for the ablation of stage 3 pancreatic adenocarcinoma: A registry study (DIRECT). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5322;
P
The use of IRE for curative intent tumor ablation alone or in combination with resection following induction chemotherapy in patients with locally advanced Stage 3 PDAC has acceptable safety and is associated with acceptable morbidity and mortality rates in appropriately selected patients. Clinical trial information: NCT03899649.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Identification of markers associated with toxicity of FOLFIRINOX in patients over 70 years with digestive cancers. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5305;
However, alternative regimens/strategies should be developed to enhance efficacy and reduce AEs. Particular attention to vulnerabilities detected using G8 and managed through MGA is of importance to reduce toxicity.
- Lonsurf (trifluridine/tipiracil) / Otsuka, Sulanda (surufatinib) / Hutchmed
Surufatinib combined with TAS-102 in third- or later-line therapy of patients with metastatic pancreatic cancer (mPDAC): An open-label, single-arm, phase II study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5288;
P2
This trial is ongoing and further molecular biomarkers exploration are warranted. Clinical trial information: NCT05481463.
- Zepsun (donafenib) / Suzhou Zelgen
Postoperative adjuvant hepatic arterial infusion chemotherapy combined with donafenib in hepatocellular carcinoma with solitary large tumor and microvascular invasion: A multicenter, prospective, single-arm, phase II trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5284;
P2
5 cm and MVI. Clinical trial information: NCT04962958.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Effect of triplet regimen (single-agent chemotherapy plus anti-PD-1 antibody and tyrosine kinase inhibitors) on survival compared to chemotherapy in the second-line treatment of advanced biliary tract cancer: A retrospective analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5281;
Standard chemotherapy was Cohort B: mFOLFOX or irinotecan plus capecitabine... The retrospective analysis suggests that the triple regimen as second-line treatment for advanced BTC pts may help improve the efficacy and survival, and is worthy of further prospective exploration.
- Cotellic (cobimetinib) / Exelixis, Roche, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Nab-paclitaxel and gemcitabine (modified) in combination with oral cobimetinib and encorafenib following FOLFIRINOX in patients with metastatic G12D and G12V pancreatic cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5258;
The combination of MEK and BRAF inhibitors with chemotherapy may be potentially active in pancreatic tumors (G12D and G12V). Based on the data presented, Nab-paclitaxel and Gemcitabine in combination with oral Cobimetinib and encorafenib needs to be further explored in a larger cohort of patients.
- AiRuiKa (camrelizumab) / HLB Bio Group
Hepatic artery infusion of FOLFOX chemotherapy and camrelizumab combined with sorafenib for advanced stage hepatocellular carcinoma (Double-IA-001): A phase II trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5249;
The combination of double intrahepatic infusion of FOLFOX and camrelizumab with sorafenib demonstrated encouraging results and manageable safety concerns for BCLC stage C HCC. Clinical trial information: ChiCTR2100041874.
- Second-line (2L) treatment patterns and clinical outcomes among real-world (RW) patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with FOLFIRINOX (FFX) or gemcitabine + nab-paclitaxel (GnP) in the first-line (1L). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5247;
In a RW sample of mPDAC pts, those with 1L-only had poor survival. Pts with 1L FFX + 2L GnP had a similar survival to 1L GnP + any 2L.
- Kaitanni (cadonilimab) / Akesobio
Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction cancer (GC/GEJC): A prospective, multi-center, phase II study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5242;
Pts with 1L FFX + 2L GnP had a similar survival to 1L GnP + any 2L. Pts received surgery after completing NAT with Cadonilimab (10mg/kg, iv, Q3W) and FLOT (50mg/m
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
FOLFOX as a therapeutic option in patients with hepatic failure due to liver metastasis of gastrointestinal (GI) system malignancies: A case series. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5232;
The oxaliplatin and fluorouracil/folinic acid regimen, known as FOLFOX, stands out as a viable option based on its pharmacokinetics. While our series is limited by a small number of patients, treatment with FOLFOX has proven to be feasible and may yield significant benefits in patients with severe liver dysfunction caused by GI cancer, especially when no further drainage options are available.
- irinotecan liposomal / CSPC Pharma
A phase II study of liposomal irinotecan-based chemotherapy with or without PD-1 inhibitor in patients with unresectable locally advanced or metastatic biliary tract cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4713;
Combined use of SG001 further improved clinical outcome in these pts without increased toxicity. Combination of liposomal irinotecan, 5-FU, LV and PD-1 inhibitor is a treatment strategy which is worthy of further exploration.
- Implementation of a hepatitis B screening program in patients receiving systemic anti-cancer therapy: A Canadian single center retrospective review. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4547;
Prior systemic therapy receipt was associated with failure to screen, and thus programs should include education on the necessity of screening as recommended by medical guidelines. The prevalence of HBV in this population may also be higher than previously expected, which should be explored in future research.
- Lonsurf (trifluridine/tipiracil) / Otsuka
Utilization of TAS-102 (TAS) or regorefenib (Rego) among commercially insured refractory metastatic colorectal cancer (R-mCRC) patients. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4493;
This claims level analysis highlights the disparities in access to later lines of therapy. Further analyses for characterization of the patterns of care and disparities are underway.
- 5-fluorouracil / Generic mfg.
The potential role of serial circulating tumor DNA (ctDNA) testing after upfront surgery to guide adjuvant chemotherapy for early stage pancreatic cancer: The AGITG DYNAMIC-Pancreas trial. (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_4025;
A high proportion of patients had detectable ctDNA, which appears independent of known prognostic markers. ctDNA detection was associated with earlier recurrence.
- 5-fluorouracil / Generic mfg.
NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA). (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3960;
P3
Both OS and DFS were improved with Chemo+CRT in node negative pts. Chemo+CRT did not increase Gr 4 or 5 AEs compared to chemo.
- Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01. (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3959;
Upfront multi-omic profiling of PDAC can be successfully incorporated into a multicenter randomized trial. While we have observed PP improved PFS and ITT longer OS favouring GnP in this cohort without gBRCA 1/2 or PALB2m, the benefit of chemo for advanced PDAC patients remains poor, with 43% unable to receive 2 nd line, arguing strongly for the development of 1 st -line biomarker selected strategies.
- albumin-bound paclitaxel / Generic mfg.
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-na (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3958;
P2
EA2186 did not demonstrate a significant difference in efficacy or overall toxicity between two attenuated regimens tested in vulnerable older adults with mPDAC. These results provide important data to guide treatment decisions and goals of care discussions in this vulnerable patient population.
- Cyramza (ramucirumab) / Eli Lilly
Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial. (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3956;
P3
These results provide important data to guide treatment decisions and goals of care discussions in this vulnerable patient population. Switch maintenance with paclitaxel plus ramucirumab after 3 months of oxaliplatin-based doublets may be a new strategy in patients with HER2-negative metastatic gastric/GEJ cancer who are non-eligible for initial immune checkpoint inhibitor-based regimens according to specific guidelines and regulatory approvals.
- 5-fluorouracil / Generic mfg.
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with resectable pancreatic ductal adenocarcinoma. (E451) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3948;
Crucially, these transcriptomic signatures can also lead to reduce toxicity by avoiding the unnecessary administration of drugs predicted as ineffective for a given tumor. Nicolle R, et al.
- Ampligen (rintatolimod) / AIM ImmunoTech
Phase 2 randomized study of rintatolimod following FOLFIRINOX in patients with locally advanced pancreatic adenocarcinoma. (Hall A; Poster Bd #: 177a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3943;
P2
The final analysis will be performed after 64 events (disease progression or death) have been observed. The study is powered to detect a hazard ratio of 0.47 for median PFS with 80% power and significance level of 5%.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Kaitanni (cadonilimab) / Akesobio
A phase II study of cadonilimab plus mFOLFIRINOX as induction therapy for locally advanced pancreatic adenocarcinoma (LAPC). (Hall A; Poster Bd #: 176b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3942;
P2
Eligible pts will be administered cadonilimab (6mg/kg, intravenous drip, Day 1, every 2 weeks) plus mFOLFIRINOX (oxaliplatin 85mg/m 2 , Day 2 + leucovorin 400mg/ m 2 , Day 2 + irinotecan 150mg/ m 2 , Day 2 + 5-fluorouracil 2,400mg/ m 2 , continuous infusion for 46 hours) for a total of 4 cycles (8 weeks)...Following the 12th cycle of treatment, maintenance treatment will consist of capecitabine or S-1 in combination with cadonilimab...Additionally, pts will undergo peripheral blood next-generation sequencing (NGS) panel analysis before and after treatment to investigate the correlation between circulating tumor DNA (ctDNA) changes, surgical decisions, and prognosis. Enrollment is ongoing.
- azenosertib (ZN-c3) / Zentalis Pharma
Targeting replication stress in pancreatic cancer: A phase II trial investigating azenosertib in combination with gemcitabine in second-line advanced pancreatic cancer. (Hall A; Poster Bd #: 175b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3940;
P2
NCT06015659 is an ongoing phase II clinical trial with safety lead-in that is testing the azenosertib WEE1 inhibitor combined with gemcitabine in patients with advanced pancreatic cancer after progression or intolerance with FOLFIRINOX...JAMA Netw Open. 2023; 6(1):e2249720.